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Abstract
Background: Several studies have implicated a recently discovered gammaretrovirus, XMRV (Xenotropic murine leukaemia
virus-related virus), in chronic fatigue syndrome and prostate cancer, though whether as causative agent or opportunistic
infection is unclear. It has also been suggested that the virus can be found circulating amongst the general population. The
discovery has been controversial, with conflicting results from attempts to reproduce the original studies.
Methodology/Principal Findings: We extracted peripheral blood DNA from a cohort of 540 HIV-1-positive patients
(approximately 20% of whom have never been on anti-retroviral treatment) and determined the presence of XMRV and
related viruses using TaqMan PCR. While we were able to amplify as few as 5 copies of positive control DNA, we did not find
any positive samples in the patient cohort.
Conclusions/Significance: In view of these negative findings in this highly susceptible group, we conclude that it is unlikely
that XMRV or related viruses are circulating at a significant level, if at all, in HIV-1-positive patients in London or in the
general population.
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Introduction
Xenotropic murine leukaemia viruses (X-MLVs) are a class of
endogenous gamma retroviruses. Xenotropic murine leukaemia
virus-related virus (XMRV) is an X-MLV that has been detected
in human samples and as such, is potentially the first gammar-
etrovirus to infect humans. XMRV has been detected in samples
from patients with diseases such as prostate cancer and chronic
fatigue syndrome, and has also been detected in 1–7% of healthy
controls tested in the same studies [1–6]. The association between
XMRV and human disease is controversial with some studies
detecting XMRV in up to 87% of patients whilst others have failed
to detect XMRV infection either in patient cohorts or in the
general population [1–17].
Here we set out to assess the prevalence of X-MLVs, including
XMRV, in an HIV-1-positive patient cohort in London. HIV-1-
positive patients were investigated because those who have been
infected by a sexual route, by intravenous drug use, by perinatal
infection or iatrogenically are likely to have been at greater risk
than the general population of other viral infections spread by
similar routes (e.g. HBV, HCV, HTLV) [18–22]. Although no
definitive route of infection has so far been found for XMRV, all
four known human retroviruses, HIV-1, HIV-2, HTLV-1 and
HTLV-2, share the same routes of transmission, namely the
transfer of blood or other body fluids. We therefore hypothesised
that if XMRV or related viruses were circulating in London they
would be likely to be detected in HIV patients. We found no
evidence for X-MLV or XMRV infection in 540 DNA samples
purified from peripheral blood leukocytes of HIV-1 infected
individuals.
Materials and Methods
Ethics Statement
The University College London Research Ethics Committee
has specifically exempted this study from review because it was an
assay development, and waived the need for consent due to the
fact the patient material used was fully anonymised.
Collection and screening of HIV-1–positive samples
Samples were collected from consecutive patients attending
Mortimer Market Centre HIV service over a period of two months
and were anonymised before processing. Patients were 4.5:1
male:female, age range 15–85 yrs, median age 42 yrs, ,1%
intravenous drug users, 15% were born outside the UK. 80% of
patients were on highly active anti-retroviral therapy (HAART);
94% of those treated had a viral load ,50 copies/ml. Approx-
imately 8 ml blood was collected into a BD-vacutainer containing
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EDTA, and stored at 4uC until processing. Genomic DNA from
the buffy coat fraction was extracted using the QIAamp DNA kit
(Qiagen) and eluted in 60 ml.
TaqMan Polymerase Chain Reaction (TaqMan PCR)
TaqMan PCR of genomic DNA using primer sets 1 and 2 were
performed as described (Figure 1, Table 1) [3,12]. Sample levels
were 5 ml per PCR reaction for controls, and ,1000 ng DNA
(usually 5 ml) for patient samples per PCR reaction. Positive
controls for the TaqMan PCR were either a synthetic plasmid
encoding the target XMRV-int sequence for primer set 1 or Balb/
c mouse DNA (Sigma D4416) for primer set 2 (X-MLV-gag).
Cycling conditions were 95uC for 15 secs and annealing/extension
at 60uC for 1 min after an initial denaturation of 10 min. The
HIV-1 positive samples were checked for PCR inhibitors by
amplification of GAPDH as previously described [23].
Results
No evidence for XMRV or X-MLV sequences in leukocyte
DNA from a cohort of HIV-1 positive individuals
In order to assess the claim that XMRV infection is common in
the human population we screened leukocyte DNA purified from
anonymised blood samples of 540 HIV-1-positive patients visiting
Mortimer Market HIV service. Approximately 20% of this cohort
(,108 patients) had not been treated with any anti-retroviral
therapy. We performed TaqMan PCR using previously described
primer sets 1 (XMRV-int) and 2 (X-MLV-gag) (Fig. 1, Table 1)
[3,12]. Primer set 1 detects XMRV but was designed to
discriminate against related X-MLVs, whereas primer set 2
readily amplifies diverse X-MLV sequences present in the mouse
genome [3,12]. The positive control for primer set 1 was a plasmid
containing the XMRV integrase target sequence and the positive
control for primer set 2 was Balb/c mouse genomic DNA. We
were able to detect (at the 50% probability level) as few as 5 copies
of the XMRV-int plasmid and 0.2 pg (1/20th of a genome) of
Balb/c DNA respectively (Figs. 2A and 2B).
To assess the sensitivity of the PCRs when detecting XMRV
integrated into genomic DNA, we extracted DNA from 22Rv1
cells. This cell line contains around 10 copies of the XMRV
provirus [24]. Using primer sets 1 and 2, it was possible to reliably
amplify 1 cell equivalent of DNA. To investigate the sensitivity of
the assay through the entire extraction and amplification process,
0, 10, 50, 250 & 1000 22Rv1 cells were mixed with leukocytes
taken from HIV-1-positive patients, blinded to the operator, then
extracted using an identical protocol to the cohort samples and
amplified using primer set 2 (Table 2). All cycle threshold (Ct)
values were in the linear range of the assay (,40). Absolute values
were not calculated, as we cannot be sure that XMRV/X-MLV
sequences in the 22Rv1 cells exactly match the primer sequences.
However, it was possible to detect ten 22Rv1 cells added to the
buffy coat fraction extracted from 8 ml blood at Ct 35 (equivalent
to approximately one 22Rv1 cell per 3 million white blood cells)
(Table 2). No signal was obtained from the samples that did not
have any 22Rv1 cells added.
In the HIV patient screen, the quantity of leukocyte DNA per
patient per PCR reaction averaged 362 ng (IQR 188–468 ng, 54–
1356103 genomes). We did not detect positive PCR signals from
any of the patient DNA samples using either primer sets 1 or 2,
indicating that neither XMRV nor any other X-MLV amplifiable
with these primers were detectable in these samples. All samples
were positive for GAPDH by TaqMan PCR at expected levels,
showing that no PCR inhibitors were present.
Discussion
In order to establish whether XMRV infects the human
population and whether it is associated with human disease it is
extremely important to be able to detect and quantitate XMRV
specifically and sensitively. The majority of screens carried
out so far have used highly sensitive nested-PCR protocols
[1,2,4,7,8,10,11,13–15,17]. However, these sensitive nested pro-
tocols are prone to false-positives from contamination [14,25]
which can come from reagents, from X-MLVs growing as
contaminants in human tumour cell lines, from amplicon
contamination or from positive controls [26–28]. In order to
minimise the risk of contamination in this study, real-time PCR
was used instead of nested-PCR so that amplicons were not
routinely exposed to the laboratory environment during the
procedure. No 22Rv1 cells were grown in the laboratory until all
screens were completed.
We could not detect XMRV or any other X-MLV sequences in
HIV-1-positive patients using TaqMan PCR, suggesting that
XMRV and related viruses are either entirely absent or at least
extremely uncommon in this population cohort. There are several
possible explanations for the discrepancy between this and some
previous studies, including that XMRV does not in fact establish
infection in human peripheral blood at detectable levels, or that
Figure 1. Primer and probe positions on the XMRV genome. Diagram of the XMRV genome with the sites of the primers marked.
doi:10.1371/journal.pone.0018096.g001
Table 1. Sequences of TaqMan PCR primer/probe sets used
to screen HIV-1-positive patient leukocyte DNA.
Target Reference Primer and Probe sequences
1XMRV integrase [3] F-CGAGAGGCAGCCATGAAGG
R-GAGATCTGTTTCGGTGTAATGGAAA
P-FAM-AGTTCTAGAAACCTCTACACTC-
MGBNFQ
2 X-MLV gag [12] F-AACCGTTTGTCTCTCCTAAACCC
R-GCAGGGTAAAGGGCAGATCG
P-FAM-ACCGACAGCTCCCGTCCTCCCG-TAMRA
doi:10.1371/journal.pone.0018096.t001
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the geographic differences between the cohort studied here and
elsewhere are critical. Alternatively, the possibility that the positive
findings reported by others were due to occult laboratory
contamination should be seriously considered [29]. It has been
shown that some anti-retroviral therapies can suppress XMRV
infection [30,31], but as approximately 20% of our cohort were
untreated, this would mean that,108 patients were studied whose
samples should have contained viral loads unsuppressed by any
drugs that potentially interfere with XMRV (or X-MLV)
replication. Our negative findings are entirely consistent with
several other studies that have failed to detect any trace of XMRV
infection in HIV-positive patients [14–17]. Henrich and colleagues
[14] tested 43 HIV-infected patients (50% untreated) from Boston,
Massachusetts using nested XMRV PCR with two different sets of
primers and reported no positives. Barnes et al [15] failed to detect
any XMRV in 230 HIV-1 patients from Switzerland and the
United Kingdom using PCRs targeting XMRV gag or env
sequences. 101 of the patients tested were not receiving
antiretroviral drugs. Similarly, Kunstman et al [16], using real-
time PCR, detected no XMRV sequences in the blood cells of 562
HIV-infected men enrolled in the Chicago component of the
Multicenter AIDS Cohort Study. Finally, Cornelissen and
colleagues [17] failed to detect any XMRV by nested PCR in
93 seminal plasma samples from 54 HIV-1-infected men living in
the Netherlands. Other reported studies have focussed on
detection of XMRV in patient groups that are different from
those described here, for example, patients with chronic fatigue
syndrome [2,7–9] or prostate cancer [1,6,10,11], or to assess
whether XMRV could be responsible for conditions of unknown
aetiology [12–14,32].
At the current time there is no consensus on definitive strategies
for testing for XMRV, or X-MLVs, and it remains unclear why
the results of published studies differ so widely in their reported
prevalence of XMRV in patient populations and healthy controls,
although several independent studies have demonstrated how
PCR contamination from mouse DNA or DNA from human cell
lines infected with xenotropic MLVs might explain XMRV
detection [26–29]. Other possibilities include differences in the
patient groups studied, for example the cohort selection criteria as
well as geographic factors. There are also differences in techniques
used to detect the virus. Here, we used qPCR in order to rapidly
screen a large patient group with a high degree of sensitivity. The
use of primer set 2, which is not specific to XMRV and targets
diverse X-MLV gag sequences, allowed us to detect viruses closely
related to XMRV in addition to XMRV itself. By assaying DNA
rather than RNA we sought proviral DNA rather than evidence
for active replication. Nucleic acid testing remains the gold-
standard for monitoring blood-borne viral diseases such as HIV
and HCV, and is more specific than serological tests. Sequencing
positive PCR products provides confirmatory evidence, and can
illuminate when contamination has occurred [29].
In conclusion, this study failed to find any evidence of XMRV
or X-MLV infection in a cohort of HIV-1-positive patients. In
view of these negative findings in this highly susceptible group, we
Figure 2. Detection of TaqMan positive controls used for HIV-
1-positive leukocyte DNA sample screening. TaqMan PCR curves
are shown for amplification of serial 10-fold dilutions of positive control
DNA (A) Curves represent the triplicate amplification of dilutions of
XMRV-int-encoding plasmid from 56107- 5 copies per PCR reaction
using primer set 1. (B) Curves represent the triplicate amplification of
dilutions of Balb/c genomic DNA from 200 ng–0.2 pg per PCR.
doi:10.1371/journal.pone.0018096.g002
Table 2. TaqMan PCR results from extraction and amplification control experiments.
Sample name
Number of 22Rv1 cells added
to leukocyte sample
Expected number of XMRV genomes
per PCR reaction (calculated from input)
Primer set 2 (X-MLV-gag) TaqMan
PCR result (Ct)
A 10 8.3 35
B 250 208 31
C 0 0.00 No Ct
D 50 42 32
E 1000 833 28
22Rv1 cells were added to leukocyte samples taken from approximately 8 ml blood, extracted, and amplified using primer set 2. The expected number of copies of
XMRV (assuming 10 copies per 22Rv1 genome [24]) and the results obtained from the TaqMan PCR are shown.
doi:10.1371/journal.pone.0018096.t002
Murine Retrovirus Prevalence in Patients with HIV
PLoS ONE | www.plosone.org 3 March 2011 | Volume 6 | Issue 3 | e18096
conclude that it is unlikely that XMRV or related viruses are
circulating at a significant level, if at all, in HIV-1-positive patients
in London or the healthy population.
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